Clinical Trial Update: Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating anti-TNF therapy, vedolizumab, and tofacitinib on vascular measures in ulcerative colitis. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Entyvio (vedolizumab)
• Humira (adalimumab)
• Remicade (infliximab)
• XELJANZ (tofacitinib)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Ulcerative Colitis | Phase 4 | Status: RECRUITING